Dr Crispin Hiley

Professional statement

Dr Crispin Hiley is a highly reputable and skilled consultant clinical oncologist who currently practises at the London-based Cromwell Hospital. He is also an associate professor in clinical oncology at University College London. 

Dr Hiley specialises in all the different kinds of lung cancer and also possesses a significant amount of expertise in chemotherapy, cancer immunotherapy, radiotherapy, proton beam therapy, as well as mesothelioma, amongst many others. He is, at present, the chief investigator or principle investigator for several academic and industry clinical trials relating specifically to lung cancer, and also leads a radiation therapy-focused research group at the University College London Cancer Institute. He has been involved in writing the RCR Lung Cancer Consensus Guidelines that establish best practice for the managment of lung cancers with radiotherapy. 

Dr Hiley is also an expert in stereotactic radiotherapy (SABR) for patients with oligometastatic cancers. These are cancers that have spread to different areas (usually less than five) where SABR in combination with other cancer treatments can be used to help control the cancer. SABR can be used to treat many different cancer types e.g. lung, breast colorectal and prostate which have become oligometastatic.

Dr Hiley graduated with honours in medicine in 2005 at the University of Manchester, before going on to undertake training across the UK and abroad, at highly established hospitals such as the MD Anderson Cancer Centre, Houston, in the USA, as well as the King's College London, but to name a few. He has, to-date, published a significantly high number of articles in some of the world's most prestigious journals, including The Lancet. He is the clinical lead and lung proton therapy lead of the University College London Hospital clinical oncology lung team, and is also the current deputy lead of clinical trials for the CRUK Lung Cancer Centre of Excellence. Dr Hiley is available for second opinions.